Abstract
BackgroundPatient-reports of cancer treatments are sometimes used in oncology research and clinically when medical records are unavailable. We aimed to evaluate the accuracy of patient recall in this setting.Materials and methodsParticipants were recruited through an email request from the Dr. Susan Love Research Foundation Army of Women seeking women diagnosed with breast cancer under age 50 and within the past ten years, self-reporting to have been treated with chemotherapy. After informed consent, participants received a web-based survey that inquired about use of and type of chemotherapy and endocrine therapy received. Medical records were reviewed, and discrepancies were defined as patient-report of a different class of drug than documented in the medical record, failing to report a documented class of drug, or responding “don’t know.”ResultsOf 171 eligible participants, completed questionnaires and medical records were available for 102 (60%). Median age at diagnosis was 41 years (range 25–49), and median time from diagnosis was 65.5 months (range 7–131). Ninety-two percent had completed college. Receipt of chemotherapy was documented in the medical records of 100% of these women who self-reported a personal history of chemotherapy, and there was also 98% concordance regarding receipt of endocrine therapy (yes vs. no). However, discrepancies were identified in 29% of patients regarding chemotherapy types. Time since diagnosis did not increase the likelihood of discrepancies.ConclusionHighly educated young women diagnosed with breast cancer more than five years prior accurately report whether or not they received broad systemic treatment categories. However, self-reports regarding specific drugs should be confirmed by medical record review.
Highlights
Highly educated young women diagnosed with breast cancer more than five years prior accurately report whether or not they received broad systemic treatment categories
There are approximately 250,000 new cases of breast cancer diagnosed annually in the United States [1], and the American Cancer Society estimates there are more than 3.1 million breast cancer survivors living within the United States [2]
The objective of our study was to assess the accuracy of patient self-reports of breast cancer treatments including newer chemotherapy regimens, targeted therapy, and endocrine therapy in a group of young breast cancer survivors
Summary
There are approximately 250,000 new cases of breast cancer diagnosed annually in the United States [1], and the American Cancer Society estimates there are more than 3.1 million breast cancer survivors living within the United States [2]. A few prior studies have assessed the concordance between self-report of breast cancer treatment and medical records [5,6,7,8,9,10] These studies have demonstrated high concordance (> 80%) regarding broad categories of treatments received (e.g. surgery, radiation therapy, chemotherapy, or endocrine therapy). One study with a mean time from diagnosis to interview of 19.3 months, found a 98.4% agreement between Iowa SEER Medicare records and patient report of breast cancer treatments in a population of women aged 65+, but that study did not evaluate accuracy regarding specific. Patient-reports of cancer treatments are sometimes used in oncology research and clinically when medical records are unavailable. We aimed to evaluate the accuracy of patient recall in this setting
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
